Human cytomegalovirus (CMV) infection is common and usually results in a mild, non-specific illness in otherwise healthy individuals, followed by asymptomatic latency. However, congenital CMV (cCMV) infection during fetal development can cause severe symptoms in newborns, including developmental delays, hearing loss, and even death. It is underappreciated that CMV causes more cases of congenital disease than the 29 most commonly screened metabolic and endocrine disorders combined, and that congenital CMV is the leading cause of non-genetic sensorineural hearing loss and neurodevelopmental abnormalities in infants. Early detection of cCMV infection is critical for timely clinical intervention, including treatment with antiviral medications, which may lessen the severity of the hearing and developmental impairments associated with this infection. This seminar will review the standard of care for cCMV diagnosis, evaluation, and treatment, and explore areas of opportunity. The impacts of advocacy and education for cCMV will also be discussed.
- Understand the standard of care for cCMV diagnosis, evaluation, and treatment.
- Recognize areas in care for which evidence is lacking, unclear, or pending.
- Gain awareness of the family experience and the impact of their cCMV advocacy work.
As SARS-CoV-2 infections continue to ebb and flow, other respiratory viruses have made a big global comeback. We saw an early and large spike in respiratory syncytial virus (RSV) cases and are in the midst of the worst influenza outbreak in nearly a decade. Even before the Northern Hemisphere flu season, influenza cases began trending well above the average of the past three years, starting in Spring 2022. Other lesser-known causes of respiratory illness such as enterovirus and adenovirus have also caused outbreaks during the past year, some with additional uncommon but serious non-respiratory impacts such as acute flaccid paralysis. This webinar will examine the current trends and possible causes of the resurgence of respiratory infections in the aftermath of the pandemic.
- Understand the current trends in respiratory illness in the third year of the COVID-19 pandemic
- Review the theory of viral interference and other factors that may be shaping the resurgence of respiratory viruses
- Discuss why detecting and differentiating respiratory pathogens is important for treatment and isolation strategies
This workshop will highlight the benefits of molecular testing for common human herpes viruses.
Dr. Preeti Pancholi will discuss targeted testing for HSV & VZV using cerebrospinal fluid and swab specimens.
Dr. Megan Pesch will provide an introduction to congenital CMV infections including diagnosis, current guidelines for testing, and legislation.
Preeti Pancholi, PhD D(ABMM)
Professor of Clinical Pathology, Department of Pathology
The Ohio State University, University Hospital East
Megan Honor Pesch, MD, MS
Director, Congenital CMV Developmental Follow-up Clinic
Division of Developmental and Behavioral Pediatrics
Michigan Medicine, University of Michigan Medical School
In an effort to contain the spread of multidrug resistant nosocomial infections with Candida auris (C. auris), the BayCare Laboratory and BayCare Infection Prevention departments developed a screening algorithm to identify patients colonized with C. auris. Specifically patients admitted from Long Term Care facilities and those known to be exposed to other C. auris positive patients are tested by PCR and fungal culture. Patients are kept in isolation until the results of the test are known. Validation of the PCR assay followed CAP recommendations and included accuracy, sensitivity and specificity studies.
- Discuss the impact of aurisinfection in the healthcare system
- Review screening algorithms
- Discuss laboratory test validation
- Review results and lessons learned from the past 6 months of screening
Accurate and cost-effectiveness detection of SARS-CoV-2 infection is an essential component of efforts to treat patients and to contain spread of the virus in the community. Molecular and antigen tests are targeted for early diagnosis while immunoassays have a preeminent role in understanding longitudinal immunity, and in vaccine development and response. This symposium is presenting the current diagnostic modalities for SARS-CoV-2 through the contributions of international experts. A multiplicity of experiences in testing COVID-19 individuals and monitoring the immune response after natural infections or vaccination, outlining the appropriate use of the different diagnostic tools.
SARS-CoV-2 continues to evolve and surveillance of variants is a necessity. Routine analysis of genetic sequence data allows the identification and characterization of variant viruses and aids in the investigation of how variants impact COVID-19 disease severity, the effectiveness of vaccines and treatments as well as diagnostic test accuracy. This webinar will discuss one laboratory’s approach to routine genomic surveillance for rapid identification of new mutations, and discuss the use of Simplexa® SARS-CoV-2 Variants Direct (RUO)* as a tool to rapidly identify mutations associated with variants of interest and concern together with next generation sequencing.
– Describe the concept of SARS-CoV-2 genetic mutation and how genetic variability could impact public health, medical initiatives, and diagnostic testing.
– Explore testing algorithms that could help identify variants with potential medical importance.
– List the major types of next generation sequencing platforms and compare and contrast test selection methods between NGS and multiplex real-time RT-PCR.
The DiaSorin Molecular Simplexa® SARS-CoV-2 Variants Direct kit is a Research Use Only (RUO) assay intended for the in vitro qualitative detection and differentiation of the mutations N501Y, E484K, E484Q and L452R present in the genome of SARS-CoV-2 in nasal and nasopharyngeal swab specimens from patients with known SARS-CoV-2 infection.
This webinar explores:
- SARS-CoV-2 variants and surveillance programs
- Simplexa® SARS-CoV-2 Variants Direct (RUO) assay description
- Liaison® MDX melting curve analysis and internal data
**For Research Use Only. Not for use in diagnostic procedures.**
There are tick-borne diseases beyond what causes Lyme disease. Different geographies have differing prevalence’s of tick-borne infections. In the northeastern USA, some of the other infectious agents are Anaplasma phagocytophilum, Babesia species and Ehrlichia species.
This talk will describe our experiences on the processes used to implement a multiplex molecular laboratory developed test (LDT) for the detection of A. phagocytophilum, Babesia spp. and Ehrlichia spp. in a clinical reference laboratory. We will discuss various testing options including assay types and ordering algorithms. Our experiences and lessons learned after implementation will be discussed, including the testing challenges we had related to COVID-19.
- Describe the various methods available for detection of Anaplasma, Babesia and Ehrlichia
- Understand the process of LDT validation
- Discuss advantages and limitations of in-house testing
To receive credit for this webinar visit Labroots
There has been a major development in the serologic diagnosis of Lyme disease. All parties agree (as before) on the paradigm of “Two Tier Testing”. The “Old” recommendation is called STTT, or Standard Two Tier Testing (ELISA reflexed to IgG and IgM WB). There are well known drawbacks and problems with this, acknowledged by the CDC and many specialists in the field. This led to the development and adoption of an improved paradigm called MTTT, or Modified Two Tier Testing. Modified Two Tiered Testing is well validated, the associated tests have been FDA cleared and they’ve been shown to perform equal to or superior to STTT in all stages of Lyme infection.
Another change is the continued appreciation of co-infections (one tick bite transmitting multiple pathogens), with implications of the types of diagnostic tests, including the available PCR tests, to be ordered in symptomatic persons following tick bites. Finally, there continues to be new emerging TBDs, including Anaplasma, Babesia, and Ehrlichia, plus further geographic spread of the more traditional well-known agents.
- Enable participants to appreciate the prevalence and epidemiology of these TBDs.
- Understand the differences between MTTT and STTT for Lyme serologic testing.
- Appreciate co-infections and the role of PCR in acute TBD panels.